Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...
"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...
Credit: Getty Images. The approval was based on data from the phase 3 EMPEROR-Reduced trial. The Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) to reduce the risk of ...
Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...
Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure ...
(RTTNews) - Merck & Co Inc.(MRK), known as MSD outside the U.S. and Canada, announced Thursday the initiation of VICTOR (VerICiguaT in adults with ChrOnic heart failure and Reduced ejection fraction), ...
The US Food and Drug Administration has approved empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for the treatment of patients who have ...
Human heart, computer artwork. Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback